Urologie Update
| 21.07.2025 | O. Efimov | Korrektes Management von Paravasaten |
| 28.07.2025 | J. Kwe | Vorstellung der NIAGARA Studie |
| 04.08.2025 | A. Pevnzner | Optimierung von ORBIS-Medication-Anordnungen |
| 11.08.2025 | J. Kwe | Management von Koageltamponaden der Harnblase |
| 18.08.2025 | M. Hallaschek | Del Muro et al.; “Retifanlimab in advanced penile squamous cell carcinoma: The Phase 2 ORPHEUS Study, Eur Urol Onc 2025 |
| 25.08.2025 | C. Rothmann | Soderberg et al.; “Percutaneous nephrolithotomy vs retrograde intrarenal surgery for renal stones: a Cochrane Review, BJUOI 2024 |
| 01.09.2025 | V. Menzel | DeLong et al.; "Long-Term outcomes of Recurrent Bulbar Urethral Stricture Treatment With the Optilume Drug-Coated Balloon: Five-Year Results From the ROBUST I Study", JU 2025 |
| 08.09.2025 | K. Sonntag | Eraky et al; “Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications and outcomes of BCG vs Gemcitabine/Docetaxel”, BJUI 2025 |
| 15.09.2025 | V. Kestel | Wang et al; “Real-World Experience with a commercial circulating tumor DNA assay in non-muscle-invasive bladder Cancer |
| 22.09.2025 | W. Koch | Song et al; "Stereotactic body radiation therapy for primary renal cancer and genetic markers of response: A phase 2 trial", EUO 2025 |
| 29.09.2025 | L. David | Connor et al; “Combination cytoreductive surgery, radiotherapy, or ablation for de novo metastatic prostate cancer: The IP2-ATLANTA Internal Pilot, Phase 2, randomised controlled Trial”, EUO |